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Edited by Shou-Wei DingAbstract RNA interference (RNAi), a sequence-speciﬁc RNA
degradation mechanism mediated by small interfering RNA
(siRNA), can be used not only as a research tool but also as a
therapeutic strategy for viral infection. We demonstrated that
intracellular expression of short hairpin RNA (shRNA) targeting
human cyclin T1 (hCycT1), a cellular factor essential for tran-
scription of messenger and genomic RNAs from the long termi-
nal repeat promoter of provirus of human immunodeﬁciency
virus type 1 (HIV-1), could eﬀectively suppress the replication
of HIV-1. We also showed that downregulation of hCycT1 did
not cause apoptotic cell death, therefore, targeting cellular factor
hCycT1 by shRNAs may provide an attractive approach for ge-
netic therapy of HIV-1 infection in the future.
 2005 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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Acquired immune deﬁciency syndrome (AIDS), caused by
human immunodeﬁciency virus type 1 (HIV-1), has reached
pandemic degree in many parts of the world with no quick
solution in sight. Although the development and use of double
or triple combinations of anti-retroviral drugs for the treat-
ment of HIV-1 infection has led to dramatic improvements
in the lives of many HIV-infected individuals, the therapy can-
not eﬀect a radical cure of the virus and may result in drug-
resistant viral variants. Therefore, it is imminent to develop
new antiviral therapeutic or preventive approaches, and
RNA interference (RNAi) holds considerable promise in this
respect.
RNAi is a process in which double-stranded RNA triggers
the silencing of gene expression in a sequence-speciﬁc manner
[1,2]. In mammalian cells, RNAi can be triggered by 21-nucle-
otide (nt) small interfering RNA (siRNA) duplexes [3,4]. The
siRNA can be delivered as synthetic RNA or short hairpinAbbreviations: RNAi, RNA interference; siRNA, small interfering
RNA; shRNA, short hairpin RNA; HIV-1, human immunodeﬁciency
virus type 1; hCycT1, human cyclin T1; P-TEFb, positive transcription
elongation factor b
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zyme Dicer [5]. The ability to stably express siRNA/shRNA
using viral vectors renders the possibility of using RNAi as a
form of gene therapy to speciﬁcally inhibit viral infection. Pre-
viously reports have shown that RNAi can be used to success-
fully downregulate the expression of a number of HIV-1 genes
including gag, pol, tat, vif, nef and rev, and reduce HIV-1 infec-
tivity [6–18]. However, the high mutation rate of HIV will lead
to viral mutants that can escape from the inhibition of siRNAs
targeting viral genes [19–21]. Therefore, RNAi-mediated
knockdown of cellular factors implicated in supporting the
HIV-1 life cycle oﬀers an alternative approach to overcome
this obstacle. In fact, cellular factors such as CD4, CXCR4,
CCR5, NF-kB, P-TEFb, Cyclophilin A, DC-SIGN, SPT-5
and PARP-1 have been successfully downregulated, resulting
in the inhibition of HIV-1 replication and infection
[6,11,13,15,16,22–32]. However, whether downregulation of
cellular genes can result in apoptotic cell death has not been
reported.
In this report, we selected human cyclin T1 (hCycT1) as the
target for RNAi-mediated inhibition of HIV-1 replication. The
hCycT1 is a subunit of positive transcription elongation factor
b (P-TEFb) and plays a key role in the activation of HIV-1
transcription by direct interaction with the viral protein Tat
which binds to HIV-1 transactivation response element of
HIV-1 RNA [33–36]. We showed that cellular expression of
shRNAs could speciﬁcally silence hCycT1 without causing
apoptotic cell death and downregulation of hCycT1 eﬃciently
inhibited HIV-1 replication. During the process of current
work, Chiu et al. [24] showed that silencing hCycT1 with syn-
thetic siRNA could suppress HIV replication, and our obser-
vation with shRNA is supporting their conclusions.2. Materials and methods
2.1. shRNA design and plasmid constructs
We used the siRNA design tools (http://www.ambion.com/techlib/
misc/siRNA_tools.html) to ﬁnd the candidate target sites in the
mRNAs and design the hairpin siRNA-encoding DNA oligonucleo-
tides. Five targeting sites of hCycT1 were selected and their coordi-
nates were according to the sequence of GenBank NM001240: CT-1,
GAACTTTCTTATCGCCAGC (100–118); CT-2, CAGCCTTGTTT
CTAGCAGC (257–275); CT-3, CACTGAAAGAATACCGCGC
(1163–1181); CT-4, GCCAAGAGTACTAAATCCT (1174–1792);
CT-5, GCCAATGGTCACAACACGA (1936–1955). After we showed
the functionality of these shRNAs, we saw a report by Chiu et al., that
a synthetic siRNA to hCycT1 could eﬀectively inhibit HIV-1 replica-
tion [24], therefore, we also made a corresponding shRNA constructation of European Biochemical Societies.
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Tat, LucF, LucR and Daxx that targeted HIV-1 Tat (TAT-
GGCAGGAAGAAGCGGA), ﬁreﬂy luciferase (CATTATCCTCTA-
GAGGATG), Renilla luciferase (GTAGCGCGGTGTATTATAC)
and Daxx (GGAGUUGGAUCUCUCAGAA), respectively [7,13,37].
All of the siRNA sequences were converted to shRNAs with the loop
sequence of UUCAAGAGA and cloned as double-stranded DNA oli-
gonucleotides between BamHI and HindIII sites of the shRNA expres-
sion vector pSilencer-H1 (3.0) (Ambion, USA). All constructs were
veriﬁed by sequencing.
Plasmid pNL4-3lucRE carrying the HIV-1 cDNA clone with a
ﬁreﬂy luciferase gene inserted into the nef gene of pNL4-3 and plasmid
pJRFL carrying env gene were obtained through the National Insti-
tutes of Health AIDS Reagent Repository [38,39].
2.2. Cell culture and transient transfection
HeLa and 293T cells were obtained from China Center for Type
Culture Collection (CCTCC), Wuhan, China. Cells were cultured
and maintained in DMEM (Dulbeccos minimal essential medium)
containing 10% heat-inactivated fetal bovine serum (FBS) (Hyclone),
2 mM L-glutamine (Gibco-BRL) and 100 U/ml of penicillin and
100 lg/ml of streptomycin (Gibco-BRL) in a humidiﬁed incubator
(37 C, 5% CO2). U373-MAGI-CCR5e cells (NIH, USA) was a sub-
clone of U373MG cells expressing CD4 linked to neomycin resis-
tance gene, the HIV-1-LTR-b-gal sequence linked to hygromycin
resistance gene and a modiﬁed CCR5 gene linked to a puromycin
resistance gene [40]. The cells were cultured and maintained in
DMEM containing 10% FBS, 0.2 mg/ml G418, 0.1 mg/ml hygromy-
cin B, and 1.0 lg/ml puromycin (Invitrogen). Twelve hours before
transfection, cells were seeded onto plates (Falcon) in DMEM con-
taining 10% FBS. Approximately 50–70% conﬂuences were plated.
Transfections of shRNAs expression plasmid and control plasmid
were performed using Lipofectamine 2000 (Invitrogen). Cells were
incubated in the transfection mixture for 6 h, and then added anti-
biotic-free DMEM to each well. In order to harvest the cells in dif-
ferent time, the transfected cells were trypsinized and washed, then
stored 20 C for Western blot analysis.2.3. Western blot
The transfected cells were harvested and rinsed twice with phos-
phate-buﬀered saline, pH 7.4 (PBS; Hyclone). Cell extracts were pre-
pared with lysis buﬀer (50 mM Tris–HCl, pH 7.4; 150 mM NaCl;
1 mM PMSF; 1 mM EDTA; 5 lg/ml Aprotinin; 5 lg/ml Leupeptin;
1% Triton-100; 1% sodium deoxycholate; 0.1% SDS) and cleared by
centrifugation at 12000 · g and 4 C. Total protein concentration in
clear lysates was measured using the Bio-Rad protein assay kit (Bio-
Rad) with bovine serum albumin as a standard according to the
manufacturers instructions. Proteins of 20 lg in total cell lysates were
subjected to 8% SDS–PAGE, and the resolved proteins were trans-
ferred onto a polyvinylidene diﬂuoride membrane (PVDF; Invitrogen).
After blocking with PBS containing 10% non-fat milk for 1 h at room
temperature, membranes were incubated with mouse monoclonal anti-
body to hCycT1 (Novocastra) or b-actin (KPL) in PBS containing
0.5% Tween 20 overnight at 4 C. The blot was detected by peroxidase
labeled goat anti-mouse secondary antibody (KPL) and chemilumines-
cent substrate (KPL) and exposed to X-ray ﬁlm (FUJI superRX).2.4. Propidium iodide staining
Cells treated with shRNA were trypsinized and washed, then resus-
pended in PBS, ﬁxed in 70% ethanol, and stored at 20 C overnight.
In preparation for apoptosis analysis, the cells were pelleted, resus-
pended in 1 ml of PBS containing 0.2 mg/ml propidium iodide (PI)
and 0.15 g/ml RNase A, and incubated at 37 C for 30 min in dark.
Stained cells were analyzed on ﬂow cytometry (FACSan, Beckman
Coulter). The apoptotic index was calculated by scoring no less than
104 cells. All observations were reproduced at least twice by indepen-
dent experiments.
2.5. TUNEL labeling assay
Cells were grown on coverslips in 24-well plates and transfected with
shRNA constructs. Later, the cells were ﬁxed with 4% (w/v) parafor-
madehyde in PBS for 1 h at room temperature, permeabilized with
0.1% Triton X-100 in 0.1% sodium citrate. The cells were subsequentlyincubated with TUNEL reaction mixture (Roche) at 37 C for 30 min.
The patterns were visualized and recorded using ﬂuorescence micros-
copy with a digital camera (Nikon).
2.6. Luciferase activity assay
Luciferase activity was quantiﬁed using a Bright-Glo Luciferase
Assay System Kit (Promega) in accordance with the manufacturers
instructions. After transfection or infection, 100 ll substrate solution
was added per well and incubated for 2 min, and chemolumines-
cence was measured in a luminometer (Tecan GENios). All of the
values were expressed as a mean of three independent
experiments.
2.7. Preparation of viral stocks and virus infection
Fresh viral stocks were prepared by co-transfection of 293T cells
with 5 lg of pNL4-3LucR-E- and 5 lg of pJRFL with Lipofect-
amine 2000 reagent in a 10 cm2 tissue culture dish. After 48 h, the
cells were washed once with phosphate-buﬀered saline (PBS), and
newly produced viral particles were harvested over 3 h in 0.5 ml of
fresh medium and were then ﬁltered in a 0.45 lm ﬁlter. The concen-
tration of p24 antigen released into cultured media was measured by
ELISA (RETRO-TEK). For virus infection, we plated U373-MAGI-
CCR5e cells at 0.6 · 105 cells per well (24 well plate), and the cells
was 30% conﬂuent one day after plating. After 12 h, transfection
was done as described above. On the second day, virus was diluted
to the concentration of 0.05, 0.1, 0.2, 0.4, 0.8 ng/ll of p24 in culture
medium and 150 ll of virus was added to each well (12-well plate).
DEAE Dextran was added at a ﬁnal concentration of 20 lg/ml.
After 2 h in a 37 C, 5% CO2 incubator, 1–2 ml of fresh culture
medium was added to each well. Virus samples were tested in dupli-
cate.
2.8. X-gal staining
After U373-MAGI-CCR5e cells were infected for 2 days, cells were
washed twice with PBS and were then ﬁxed with 1% formaldehyde,
0.2% glutaraldehyde in PBS for 5 min at room temperature. Then cells
were washed with PBS to remove traces of formaldehyde and glutaral-
dehyde and were treated with staining solution (5 mM potassium fer-
rocyanide, 5 mM potassium ferricyanide, 2 mM MgCl2, and 0.2% X-
gal in PBS) for 1–16 h at 37 C. When the blue-stained cells were vis-
ible, X-Gal solution was removed and cells were covered with PBS and
photographed.3. Results
3.1. Speciﬁc inhibition of hCycT1 protein expression by shRNAs
targeting hCycT1
The protein hCycT1 is a subunit of the P-TEFb complex
that interacts with the transactivation domain of Tat and is
involved in the species-speciﬁc activation of HIV-1 transcrip-
tion. We ﬁrst tested whether intracellularly expressed shR-
NAs could downregulate hCycT1 expression. Six constructs
were obtained which led to expression of 6 shRNAs target-
ing hCycT1 (named as shRNA CT1–6, respectively). The
shRNA CT6 corresponded to a synthetic siRNA sequence
that had been shown to be capable to inhibit hCycT1
expression [24] and thus was used for comparison of eﬀec-
tiveness of shRNAs. The shRNA LucR that targeted specif-
ically to Renilla luciferase gene was used as negative control.
HeLa cells were transfected with individual shRNA-express-
ing constructs, and expression of hCycT1 was subjected to
Western blot analysis with speciﬁc antibody to hCycT1. As
shown in Fig. 1A, the expression of hCycT1 in HeLa cells
transfected with hCycT1 shRNA CT-4 (lane 4) and shRNA
CT-5 (lane 5) was signiﬁcantly downregulated compared
with that of control shRNA LucR (lane 7) whereas shRNA
CT-6 (lane 6) only slightly reduced hCycT1. In contrast,
Fig. 1. Speciﬁc down regulation of human CycT1 expression by
shRNAs. (A) HeLa cells were transfected with 0.8 lg shRNA-
expressing constructs or mock transfected in 24 well plates, and
hCycT1 expression was subjected to Western blot analysis after 48 h.
Lanes 1–6 represent hCycT1 shRNAs 1–6, respectively. M indicates
mock-transfected control while lane 7 is negative control shRNA
LucR. (B) and (C) HeLa cells were transfected with 0 to 1.6 lg (B) or
0.8 lg (C) CT-4 shRNA construct in 24 well plates for 48 h (B) or 0,
12, 24, 36, 48 h (C), and then subjected to western blot analysis. b-
Actin expression was used as internal control for all the western blot
experiments.
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no eﬀect on the expression of hCycT1, indicating positional
eﬀects of targeting sites. Moreover, the level of b-actin was
unaﬀected by either control or hCycT1 shRNAs. These re-
sults indicated that intracellularly generated shRNAs couldFig. 2. Knockdown of hCycT1 by hCycT1 shRNA-4 does not induce apopto
shRNA or negative control LucR shRNA constructs in 6 well plates and 48 h
the nuclei of apoptotic cells was stained by TUNEL labeling assay with ﬂuospeciﬁcally downregulate hCycT1 expression. Similar phe-
nomena were demonstrated in 293T and U373-MAGI-
CCR5e cells (data not shown). As hCycT1 shRNA CT-4
was the most eﬀective shRNA to suppress the expression
of hCycT1 in all the cell lines mentioned above, we used
hCycT1 shRNA-4 for further studies.
We next tested whether the inhibition of hCycT1 by shR-
NAs was dose- and time-dependent. As shown in Fig. 1B, in-
crease of the quantity of the hCycT1 shRNA-expressing
plasmid from 0.2 to 1.6 lg per well lowered the expression level
of hCycT1 accordingly. Moreover, hCycT1 expression was de-
tected at diﬀerent times post transfection and the results
showed (Fig. 1C) that down regulation of hCycT1 were most
signiﬁcant 36 h post transfection. These results indicated that
the inhibition of hCycT1 expression by shRNAs was both
dose- and time-dependent.
3.2. Knockdown of hCycT1 protein did not induce apoptosis
The prerequisite for inhibition of virus replication by
interference with cellular gene expression is that knocking
down the cellular gene would not lead to host cell apoptosis.
To test the eﬀect of hCycT1 on cell growth, we transfected
shRNA CT-4 and control shRNA into diﬀerent cell lines
including 293T, HeLa and U373-MAGI-CCR5e. The trans-
fection eﬃciency was determined by co-transfection of a re-
porter plasmid, pEGFP-C1, to conﬁrm that the transfection
eﬃciency was similar. Forty-eight hours post-transfection,
cells were harvested and sub-G1 peak were determined by
ﬂow cytometry through apoptosis staining. The result
showed that there was no statistically signiﬁcant diﬀerence
in sub-G1 between cells treated with control shRNA and
those treated with hCycT1 shRNA in monolayer cell culture
(Fig. 2A). Furthermore, the knockdown of hCycT1 did not
aﬀect the cell cycle through comparing with the control andsis. HeLa cells were transfected with 4 lg hCycT1 shRNA CT-4, Daxx
later, the sub-G1 peak was examined using FACS by PI staining (A) or
rescein (B).
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TUNEL labeling assay through analyzing the DNA frag-
ments of the treated cells. The result showed that no apop-
totic cells were found whereas, as a control, knocking down
the Daxx protein in HeLa cells can cause apoptosis (Fig.
2B). These data indicated that down regulation of hCycT1
did not induce signiﬁcant apoptosis of transfected cells and
hCycT1 could be used as a potential target for inhibiting
HIV-1 replication.3.3. Knockdown of hCycT1 protein inhibits HIV-1 replication in
293T cells
We used luciferase-expressing HIV-1 clone (pNL4-3LucR-
E-) to test whether knockdown of hCycT1 by shRNA could
inhibit HIV replication. We co-transfected shRNA and
pNL4-3LucR-E- plasmid into 293T cells and measured the
luciferase activity at 48 h post transfection. As shown in
Fig. 3A, the shRNA CT-4 reduced the luciferase activity sig-
niﬁcantly when compared with the cells transfected with
control Renilla luciferase shRNA LucR or mock (Fig.
3A). The inhibition eﬃciency of diﬀerent hCycT1 shRNAs
was in accordance with the down regulation of hCycT1 pro-
tein expression levels (Fig. 1A and Fig. 3A). The inhibition
time course and eﬃciency of the hCycT1 shRNA CT-4 was
similar to that of shRNAs LucF and Tat which targeted the
ﬁreﬂy luciferase reporter and HIV-1 Tat gene, respectively,
indicating the strong inhibition eﬀect of shRNA CT-4
(Fig. 3B). In addition, the inhibition eﬀect of shRNA is
dose-dependent as shown in Fig. 3C. Taken together, the
shRNA CT-4 to hCycT1 could inhibit HIV-1 gene expres-
sion and replication speciﬁcally and eﬃciently in 293T
cells.Fig. 3. Speciﬁc inhibition of HIV-1 replication by hCycT1 shRNAs in
293T cells. (A) 293T cells were cotransfected with 0.2 lg pNL4-
3lucRE and indicated 0.2 lg shRNAs (LucF, ﬁreﬂy luciferase
shRNA; Tat, Tat shRNA; CT-1 to CT-6, hCycT1 shRNA 1–6,
respectively and LucR, Rennila luciferase shRNA) or mock in 96 well
plates and the luciferase activity that was driven by HIV-1 replication
was examined 48 h later. (B) 293T cells were cotransfected with 0.2 lg
pNL4-3lucRE and indicated dose of CT-4, Tat, LucF or LucR in 96
well plates, 48 h later, luciferase activity assay were performed. (C)
293T cells were cotransfected with 0.2 lg pNL4-3lucRE and 0.2 lg
CT-4, Tat, LucF, LucR or Mock in 96 well plates, luciferase activity
assay were performed in 0, 12, 24, 36, 48 h.3.4. Eﬀects of hCycT1 shRNA on early stages of HIV-1
infection
We further tested the inﬂuence of the hCycT1 interference
on the early stages of HIV-1 infection with single-round rep-
lication HIV-1 viral particles. We cotransfected pNL4-3lucR-
E- and pJRFL into 293T cells and harvested the HIV-1 par-
ticles. At 12 h post transfection with shRNAs, the U373-
MAGI-CCR5e cells, which express b-galactosidase ( b-gal)
under the control of HIV-1 LTR, were infected by the viral
particles. The luciferase activity was measured at 48 h post
infection and shRNA LucF targeting the luciferase reporter
was used as control (Fig. 4 A and B). The Fig. 4A showed
that Tat and hCycT1 shRNAs dramatically decrease the
luciferase activity, indicating their signiﬁcant suppression of
viral replication. With diﬀerent doses of viral particles
(Fig. 4C), luciferase activity remained low with Tat and
hCycT1 shRNAs, suggesting that viral replication could be
inhibited regardless of the dose of viral particles used.
U373-MAGI-CCR5e cells contain a single integrated copy
of HIV-1 LTR linked to the b-gal gene. We next examined
whether shRNAs against hCycT1 could suppress the activa-
tion of integrated HIV-1 LTR promoter. Cells were treated
according to the method mentioned above and were stained
by X-gal. Fig. 4D showed that shRNA directed against
hCycT1 resulted in very low levels of b-gal gene expression.
These results suggested that the activation of integrated
HIV-1 promoter was suppressed in cells transfected with
shRNA directed against hCycT1.4. Discussion
RNAi with shRNA has been successfully utilized in a number
of recent studies in cultured mammalian cells to reduce the
expression of speciﬁc cellular and viral genes. Here, intracellu-
larly expressed shRNA based on plasmid vector were utilized
in 293T, HeLa and U373-MAGI-CCR5e cells to assay whether
it could inhibit the expression of the hCycT1 protein and, in
turn, whether inhibition of hCycT1 expression could modulate
Fig. 4. Suppression of HIV-1 infection by knockdown of hCycT1
protein. (A) U373-MAGI-CCR5e cells were transfected with 0.8 lg
Tat, LucF, CT-4 and LucR shRNAs or mock transfected in 24 well
plates and 12 h post transfection, the cells were infected by 64 ng (p24)
single-round replication HIV-1 particles. The luciferase activity was
analyzed after 48 h. (B) and (C) U373-MAGI-CCR5e cells were
transfected with indicated dose (B) or 0.8 lg (C) of Tat, LucF, CT-4
and LucR shRNAs in 24 well plates and 12 h post transfection, the
cells were infected by 64 ng (p24) (B) or 8, 16, 32, 48, 64 ng (p24) (C)
single-round replication HIV-1 particles. The luciferase activity was
analyzed after 48 h. (D) Inhibition of HIV-1 5 0-LTR promoter
activation in cells transfected with CT-4 shRNA in 24 well plates
shown by X-gal staining. U373-MAGI-CCR5e cells were transfected
with 0.8 lg CT-4 and LucR shRNAs or mock transfected in 24 well
plates and 12 h post transfection, the cells were infected by 64 ng (p24)
single-round replication HIV-1 particles. 48 h later, the cells were
stained by X-gal and photographed.
3104 Z. Li et al. / FEBS Letters 579 (2005) 3100–3106HIV-1 gene expression and replication. In this study, we have
demonstrated that hCycT1 shRNA suppressed hCycT1 protein
expression but did not induce signiﬁcant apoptosis in cultured
cells. We have also shown that knockdown of hCycT1 expres-
sion by RNAi inhibited HIV-1 replication speciﬁcally and eﬀec-
tively. Furthermore, we observed the correlation between the
levels of downregulation of hCycT1 expression and the inhibi-
tion of HIV-1 replication (Fig. 1B, Fig. 3B, Fig. 4B), indicating
that the replication level of HIV-1 may be dependent on the
amount of hCycT1 in cultured cells. This result was in contrast
with one previous observation that low level of hCycT1 expres-
sion does not limit HIV-1 Tat function in cultured cells [41].
Cyclins act as regulatory elements of transcription activation
protein complexes (P-TEFb) together with CDKs that func-
tion as catalytic subunits to phosphorylate carboxyl-terminal
domain (CTD) of Pol II. CDK/cyclin complexes not only reg-
ulate cell division by phosphorylating diﬀerent substrates, but
also control several cellular pathways such as signal transduc-
tion, diﬀerentiation, and apoptosis [42–44]. CDK9/cyclin T di-
rects its activity in a cell cycle independent manner and was
involved in transcription during the elongation steps [45]. This
means that hCycT1 is important for cell survival. Surprisingly,
knockdown of hCycT1 protein neither inﬂuenced the cell cycle
nor induced apoptosis in cultured cell lines, and this was con-
sistent with a previous report that knockdown of P-TEFb led
to inhibition of HIV-1 replication but not resulted in cell death
[24]. This may indicate that very low level of P-TEFb kinase
activity is suﬃcient for cell viability or the cells can compensate
for lower P-TEFb protein levels by converting kinase-inactive
P-TEFb to active forms [24]. Our results are supporting these
explanations and demonstrated that the essential genes for cell
viability like hCycT1 could also serve as target for suppression
of HIV-1 infection and replications.
In previous reports about RNAi with HIV-1 replication and
infection, chemically synthesized siRNAs were most com-
monly used [9,11,24], however, synthetic siRNAs do not per-
sist for long period in cells and are not feasible to be
delivered into the vast number of target cells like T lympho-
cytes and macrophages. Here, we showed that intracellular
expression of shRNAs from a DNA vector could eﬃciently
downregulate hCycT1 expression and speciﬁcally suppress
HIV-1 replication. Thus, this result renders a possibility to de-
liver the anti-HIV shRNA-encoding genes by viral vectors into
target cells and stably express the shRNAs. In this study, the
shRNA CT-6 to hCycT1 was designed according to the se-
quence of a synthetic siRNA which was eﬀective to silence
hCycT1 [24], however, the shRNA CT-6 appeared not as eﬃ-
cient as the corresponding synthetic siRNA (Fig. 1A) although
we did not have direct comparison. Instead, the shRNA CT-4
to hCycT1 was most eﬀective among the 6 shRNAs to hCycT1
(Fig. 1A). The discrepancy suggests that the eﬃciency of DNA
vector-derived shRNA and the synthetic siRNAs may have
diﬀerent requirements for sequence conﬁguration and, thus,
the sequence of synthetic siRNA might not be translated into
shRNA without changing its eﬃciency.
Taken together, this study demonstrated the hCycT1 could
be a promising cellular target for suppression of HIV-1 replica-
tion by DNA-based shRNAs. Our future study will focus on
the delivery of shRNA-encoding genes into primary cells, such
as T lymphocytes, monocytes and macrophages by lentiviral
vectors and examine the feasibility to use hCycT1 as target
in genetic therapy of AIDS.
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